The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...

Enfortumab vedotin in combination with pembrolizumab is being investigated in an extensive program in multiple stages of urothelial cancer, including two Phase 3 clinical trials in MIBC in EV-304 ...

Additionally, the trial met key secondary endpoints. The objective response rate was 67.7% in the pembrolizumab plus enfortumab vedotin arm compared with 44.4% in the chemotherapy arm (P <.00001).

Video > Bladder Cancer Video Pearls Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer — Patients with complete response can have long treatment-free interval, study suggests ...

The median OS was 33.8 months in the enfortumab vedotin-pembrolizumab arm and 15.9 months in the chemotherapy arm (sHR, 0.51; 95% CI, 0.43-0.61; P <.00001).

Enfortumab vedotin plus pembrolizumab also significantly prolonged OS with a median OS of 31.5 months vs 16.1 months for chemotherapy, reducing the risk of death by 53% (HR, 0.47; 95% CI, 0.38-0. ...

Enfortumab Vedotin With/Without Pembrolizumab in Cisplatin-Ineligible Pts With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer – An ASCO Reading Room selection September 18 ...